A year ago, in Medical Forum, we outlined the progress at the Perron Institute in developing the neuroprotective peptide poly-arginine-18 (R18; renamed ARG-007) for acute ischaemic stroke. Since then, there have been significant developments that suggest a major breakthrough is imminent. In February, our Canadian colleagues published the results of their phase III trial of the neuroprotective peptide, NA-1, also called nerinetide. The NA-1 trial randomised 1105 patients with acute ischaemic stroke to receive nerinetide or placebo, in addition to standard stroke care comprising endovascular thrombectomy, with or without thrombolysis, with tissue plasminogen activator (tPA). Dr David Blacker, Neurologist, Hollywood.…
This content is restricted to site members. If you are an existing user, please log in. New users may register below.